Ki67 scores are clinically relevant particularly for early-stage luminal/HER2-negative breast cancer in post-menopausal patients, whereas treatment choices for triple-negative and HER2-positive cancers are mostly independent of Ki67 [25]. This evidence concerns the gene MKI67 and breast cancer.